Jason Helfstein, Oppenheimer head of internet research, joins 'The Exchange' to discuss Spotify as the stock sinks on Q2 ...

Fintel reports that on July 29, 2025, Oppenheimer upgraded their outlook for Sarepta Therapeutics (NasdaqGS:SRPT) from ...

Sarepta Therapeutics ( NASDAQ: SRPT) was upgraded to Neutral from Underweight at J.P. Morgan as it sees FDA's Elevidys hold removal recommendation in ambulatory patients as a clear win.

Carvana Co. (NYSE:CVNA) is one of the best multibagger stocks according to hedge funds. On July 25, 2025, Oppenheimer analyst ...

Jensen Huang believes questions of whether artificial intelligence (AI) could destroy humanity are fear-mongering — and get ...

Visa and Mastercard are expected to report higher quarterly profits this week on steady consumer spending, and analysts will ...

The strategist — an industry veteran of 40 years who joined Goldman Sachs in 2002 — spoke to Bloomberg News about the outlook ...

Shares of Sarepta Therapeutics surged Tuesday morning after the company said it had been informed by the Food and Drug ...

This isn’t a generic re-run. These screenings are a testament to Nolan’s continued support for the IMAX format and enable ...

Sarepta stock sees upgrades and price hikes as analysts reassess Elevidys prospects following a favorable FDA development.

Most traders follow the headlines. Tim Melvin follows the money. See how Tim, Anne-Marie Baiynd, and Ryan Faloona are ...